A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges

Effect of HIV-infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract

(2015) Mackenzie L Cottrell et al.   ANTIVIRAL THERAPY

Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques

(2015) Ivana Massud et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women

(2015) Jeanne M. Marrazzo et al.   NEW ENGLAND JOURNAL OF MEDICINE

The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge

(2015) J. Radzio et al.   Science Translational Medicine

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

(2015) Chasity D. Andrews et al.   Science Translational Medicine

Cabotegravir long-acting for HIV-1 prevention

(2015) Chasity D. Andrews et al.   Current Opinion in HIV and AIDS

The current status of the use of oral medication to prevent HIV transmission

(2015) Kenneth H. Mayer et al.   Current Opinion in HIV and AIDS

Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission

(2015) Martina Kovarova et al.   PLoS Pathogens

A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis

(2014) A G A Jackson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus

(2014) C. D. Andrews et al.   SCIENCE

Pharmacokinetics of Maraviroc, Raltegravir, Darunavir, and Etravirine in the Semen of HIV-Infected Men

(2013) Tony Antoniou et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature

(2013) T. Wyss-Coray et al.   Cold Spring Harbor Perspectives in Medicine

HIV Prevention by Oral Preexposure Prophylaxis

(2013) W. Heneine et al.   Cold Spring Harbor Perspectives in Medicine

Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens

(2012) Carolina Garrido et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

(2012) Matthew L. Rizk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana

(2012) Michael C. Thigpen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

(2012) Jared M. Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Attitudes and Acceptance of Oral and Parenteral HIV Preexposure Prophylaxis among Potential User Groups: A Multinational Study

(2012) Andreas B. Eisingerich et al.   PLoS One

Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice

(2012) Paul W. Denton et al.   TRENDS IN MICROBIOLOGY

Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study)

(2011) Cyril Clavel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection

(2011) Rikke Olesen et al.   JOURNAL OF REPRODUCTIVE IMMUNOLOGY

One Percent Tenofovir Applied Topically to Humanized BLT Mice and Used According to the CAPRISA 004 Experimental Design Demonstrates Partial Protection from Vaginal HIV Infection, Validating the BLT Model for Evaluation of New Microbicide Candidates

(2011) P. W. Denton et al.   JOURNAL OF VIROLOGY

Generation of HIV Latency in Humanized BLT Mice

(2011) P. W. Denton et al.   JOURNAL OF VIROLOGY

Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir with and without Maraviroc Coadministration

(2010) Silvia Baroncelli et al.   ANNALS OF PHARMACOTHERAPY

Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation

(2010) G. van 't Klooster et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Raltegravir Penetration in Seminal Plasma of Healthy Volunteers

(2010) A. Calcagno et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

(2010) Robert M. Grant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systemic Administration of Antiretrovirals Prior to Exposure Prevents Rectal and Intravenous HIV-1 Transmission in Humanized BLT Mice

(2010) Paul W. Denton et al.   PLoS One

Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse Model

(2010) C. Preston Neff et al.   PLoS One

Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women

(2010) Q. Abdool Karim et al.   SCIENCE

High Concentration of Raltegravir in Semen of HIV-Infected Men: Results from a Substudy of the EASIER-ANRS 138 Trial

(2009) C. Barau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

(2009) Lieven Baert et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies

(2009) Marie-Claude Boily et al.   LANCET INFECTIOUS DISEASES

Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice

(2008) Paul W Denton et al.   PLOS MEDICINE